For more information, availability and pricing options for sponsorship/exhibition opportunities at the event, please contact Jon Liong at email@example.com.
IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of human data science a reality. IQVIA’s approach to human data science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, transformative technology and analytics with extensive domain expertise.
IQVIA Greater China R&D
After 21 years of expansion in Greater China (first office opened in 1997), we now have more 2,200 employees in Greater China. We have developed an integrated drug development offering to help companies of all sizes and types grow and succeed. Our infrastructure and capabilities in Greater China include: offices in Beijing, Shanghai, Dalian, Hong Kong and Taipei, allowing it to serve all major population centers and study sites; a world-class Central Lab in Beijing, with biomarker and pathology capabilities; and customized local solutions through our local subsidiary, Kun Tuo.
Chubb is the world’s largest publicly traded P&C insurance company and the largest commercial insurer in the U.S. With operations in 54 countries and territories, Chubb provides commercial and personal property and casualty insurance, personal accident and supplemental health insurance, reinsurance and life insurance to a diverse group of clients. As an underwriting company, we assess, assume and manage risk with insight and discipline. We service and pay our claims fairly and promptly. We combine the precision of craftsmanship with decades of experience to conceive, craft and deliver the very best insurance coverage and service to individuals and families, and businesses of all sizes.
Chubb is also defined by its extensive product and service offerings, broad distribution capabilities, exceptional financial strength and local operations globally. The company serves multinational corporations, mid-size and small businesses with property and casualty insurance and risk engineering services; affluent and high net worth individuals with substantial assets to protect; individuals purchasing life, personal accident, supplemental health, homeowners, automobile and specialty personal insurance coverage; companies and affinity groups providing or offering accident and health insurance programs and life insurance to their employees or members; and insurers managing exposures with reinsurance coverage.
Chubb has more than $167 billion in assets and $36 billion of gross premiums written in 2017. Chubb’s core operating insurance companies maintain financial strength ratings of AA from Standard & Poor’s and A++ from A.M. Best.
Chubb Limited, the parent company of Chubb, is listed on the New York Stock Exchange (NYSE: CB) and is a component of the S&P 500 index.
Chubb maintains executive offices in Zurich, New York, London and other locations, and employs approximately 31,000 people worldwide.
Established in 1989, OrbiMed is healthcare and life sciences-dedicated investment firm. OrbiMed manages approximately USD$14 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 400 private companies across a wide range of therapeutic categories and stages of development. OrbiMed has continued strong performance in public equity as well. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund. OrbiMed Asia manages three Asia-focused PE/VC funds, totaling over $1 billion. It has made investments in 40 companies.
For More information, please vist www.orbimed.com.
PROTECH PHARMASERVICES CORPORATION
PPC groupwas foundedin 1997, provides professional services for clinical studies to pharmaceutical and biotechnology companies.PPC group offers clinical and laboratory services in China, Taiwan, Korea and Japan. Since 1997, PPC has completed over 2000 early phase trials, including innovative phase Ipharmacokinetic, generic bioequivalence and biosimilar studies, to pharmaceuticals companies. In addition, PPC group has conducted over 400 innovative phase II-IV trials, covering all 24 therapeutic arenas. We have been audited more than 30 times by numerous regulatory authorities, including FDA, PMDA, CFDA，ANSM, NPRAand etc.
To fulfill harmonized bioequivalence standard for phase Iclinical site, PPC group has set up a phase Icenter in Taipei MacKay memorial Hospital in 2012; and co-found a phase Icenter with Xuzhou medical hospital in early 2017.Combining the strengths of Xuzhou Medical University, PPC has established strong early phase drug development especially in the bioavailability and bioequivalence research field over the past two decades. In 2018, PPC had set up 3 more dedicated Phase I Units in Xuzhou Central Hospital, Huangshi Central Hospital and Shanghai Pudong People’s Hospital.
Syneos Health is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life®visit syneoshealth.com.
Samsung BioLogics (SBL) is a global Contract Development and Manufacturing Organization, offering biologic development and cGMP manufacturing services. Our service includes cell line development, process development, analytical method development, formulation development to cGMP manufacturing in diverse scales. We provides flexible and comprehensive set of services that connect all aspects of product development through clinical and commercial production as an integrated process.
Samsung BioLogics developed successful strategic collaboration with global CDMO partners, ensuring global quality standard to provide high quality products to meet market needs and regulatory requirements. As a most qualified CDMO chosen by client, Samsung BioLogics always provides complete suite of offerings with a dedicated team to serve our service, interacting with our client proactively.
coming soon ...
ALMAC CLINICAL SERVICES
Almac Clinical Services, part of the Almac Group, has over 30 years’ experience deploying our clinical supply chain expertise and full suite of end-to-end clinical solutions to our global clients. By listening to our customers, we understand their challenges, creating patient-centric solutions that meet evolving study and industry needs.
BEIJING BIOKNOW INFORMATION TECHNOLOGY
Beijing Bioknow Information Technology Co., Ltd, founded in 2007, is dedicating to provide integrated eClinical solutions and services in China. Based on BioKnow Universal Application Platform (Bioknow-UAP), Bioknow has developed a series of electric clinical software (Bioknow eClinical Solution), including electronic data capture system (EDC), randomization and trial supply management system (RTSM), electronic patient reported outcomes (ePRO), clinical data reporting sys- tem (DMReport), medical coding system (Medcoding), Pharmaco vigilance (PV), clinical trial management system (CTMS), clinical data total management system(CDTMS), electric trial master file (eTMF), pre-clinical research management system(CRMS), and electric common technical documents (eCTD). Bioknow eClinical Solu- tion integrates the whole process of clinical research and development projects to effectively support clinical development. Bioknow plays a leading role as service provider in information technology in clinical research in China.
BESTUDY MEDICAL TECHNOLOGY
Bestudy Group was established in 2010 in Shanghai, as a leading Contract Research Organization specializing in providing high quality clinical research service for multinational and domestic bio-pharmaceuticals, medical device enterprises and medical research institutions.
Bestudy clinical services are covering the fields of drug, medical device, biological products etc, providing sponsors with professional clinical solutions and services. In November 2017, Bestudy was awarded of the title of high-tech enterprise of Shanghai Science and Technology Commission.
Bestudy service is including clinical trial design organization operation and management of phase I-IV local and global multicenter studies for innovative drug and medical device . These include but not limit to project design and preparation, IND/NDA, protocol medical writing, site selection and collaboration, clinical and medical monitoring, project management and quality control, clinical study self-inspection/CFDA, FDA inspection support/3rd party audit, drug management, data management and statistical analysis, clinical study report writing, etc. Bestudy also provides pharmacovigilance and post-market drug surveillance service during clinical study and after new product launch. In addition, Bestudy provides regulatory consultancy, agent service, HEOR for innovative new drug and medical device planned for China market launch, market entry. We also provide professional training for improvement of technical skills and talents for investigator and professionals in clinical and pharmaceutical medicine industry.
The ECCRT is a specialised clinical research training organisation focusing on the transfer of implementable knowledge in the day-to-day activities of our participants whether being starters on the job or seasoned professionals.
Our mission is to facilitate Clinical Researchers to excel in their job for the benefit of patients. We aim to achieve this by providing clinical research professionals with competencies to develop new treatments for patients more efficient, without jeopardizing quality.
The ECCRT is in its actions supportive of the Benjamin Franklin's statement: “You tell me, and I forget. You teach me, and I remember. You involve me, and I learn.”
ESTART MEDICAL TECHNOLOGY
eStart Medical Technology Co., Ltd. (eStartMed www.estartmed.net) is a Chinese domestic contract research organization (CRO) mainly specialized in Phase I trail services. eStartMed offers seamless one stop services, including registration and strategical consulting, phase I-IV study project management, QC and QA audit, protocol design, data management, biostatistics, electronic data capture (EDC).
Recent years, the core team has successfully conducted more than 100 studies including Apatinib, Pyrrolidine, Martinib, Pramipexole, Celecoxib, Lenalidomide, etc.; and in 2013 completed the first China domestic TQT clinical trial according to international standards ( Morpholine nitrazole) and multiple IQT (or CQT) studies.
EstartMed has established Phase I Clinical Trials Center along with PKUCare LuZhong Hospital. The Ward currently has 100 beds, and has been established and configured in accordance with international standards, regulated and conformed to CFDA and FDA regulations, which provides international level of Phase I clinical trial service for you.
Fountain Medical Development Limited (“FMD”) is a Contract Research Organization (CRO) that can provide clinical development services which meet international standards. FMD promises to provide high quality one-stop clinical study services including regulatory services, medical affairs, clinical operations, data management and statistics, pharmacovigilance, for domestic and multinational pharmaceutical companies or medical device manufacturers. FMD is the first CRO in China that can provide joint drug development services between China and the United States, Europe, Japan, Australia, Taiwan and other countries & regions.
Jsure Health is the leading patient recruitment organization (PRO) in China, which provides reliable service raging from feasibility study, patient recruitment, patient self-report and survey, and patient retention service with multiple online and offline channels. Jsure helps over 70 studies every year to recruit thousands patients and assists sponsors to speed up their trial progress. Jsure currently has over 200,000 patient database and provide “Drug Finder” which is the online tool for clinical trial access for patients and referral doctors. Jsure is the co-founder of the Asian Patient Recruitment Organization (APRO) in 2014 which covers China, Japan, Korea and other countries to meet the increasing demands of Clinical Trials in Asia. Jsure is well recognized in the industry by its efficient service level and high quality management standard by 30+ leading global Pharma and leading bio-pharma in China. Jsure health has been listed on China new three board stock market since 2015.
Linear is a tech-enabled, Australian clinical trial centre conducting complex First-in-Human trials for Chinese and US Biopharma helping fast track FDA, EMA and CFDA clinical programs. Leveraging digital solutions (eSource) and an extensive medical network, Linear can execute complex phase I studies including oncology, immunology and CNS trials on average 3-6 months quicker than the US. Located in Western Australia and in the same time zone as China, our dedicated China team helps companies seamlessly negotiate trials. Australia is regarded as the premier destination for early phase trials with one of the worlds best medical systems, no requirement for an IND, and generous tax incentives for R&D.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and approximately 20,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.
PRA HEALTH SCIENCES
PRA has been delivering innovative drug development solutions in China for nearly a decade and continue that work through our locations in Beijing, Shanghái and Dalian.
We strive to move drug discovery forward side-by-side with our clients, helping them to develop live-saving and life-improving drugs. We provide comprehensive clinical development and data services across all phases with our unique blend of expertise and technology. From full-service clinical development to our pioneering Embedded Solutions™ model, PRA offers a broad spectrum of solutions that meet the demands of a diverse marketplace.
As a top five CRO, we have worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of more than 75 such drugs.
PRA provides the local and global presence you need, with 15,500+ employees covering over 85 countries, combined with an in-depth knowledge of local regulations, standards of care, and the cultural customs our clients expect.
Our mission in China is to build the most comprehensive and flexible offering to support our clients with global trials, embedded teams, in-house biometrics, and local trials in China.
PROSWELL MEDICAL COMPANY
Proswell Medical Company, established in 2004, provides a wide range of world-class services for clinical trial and pharmaceutical development for domestic and oversea customers . Proswell takes on the responsibility for creating an international brand by local clinical Contracted Reasearch Organization (CRO) and promoting the development of China CRO Industry. Proswell successfully passed ISO 9001:2008 Quality Management System Certification in January 2010 and became the first local certified CRO in China.This achievement represents Proswell’s sincerity, dedication, professionality and commitment to its partners and customers to provide clinical trial service with supreme-quality and balanced-efficiency!
Shanghai Sheng Sheng Logistics Co., Ltd. is a Outstanding, professional medical and biological cold chain logistics company. Since its establishment in 2009, it has been focused on providing safe, professional and efficient cold chain logistics solutions for customers in the fields of life science, biotechnology and drug R&D. We are committed to help our customers to success in their area in China and all over the world.
Hangzhou Tigermed Consulting Co., Ltd（stock symbol: 300347） is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality.
Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 60 offices across China and 10 overseas offices in Hong Kong, Taiwan, USA, Canada, Korea, Australia, Japan, Malaysia, Singapore and India with over 3200 full time staffs. Tigermed has set up international standard SOPs and serviced more than 600 local and global clients in the conduct of over 920 clinical trials. Tigermed is recognized as “The Innovative CRO” in China，owning to our involvement of 130 innovative drugs.
For more information about Tigermed, please visit www.tigermed.net